SG11201811434RA - Antimalarial compositions and uses thereof - Google Patents

Antimalarial compositions and uses thereof

Info

Publication number
SG11201811434RA
SG11201811434RA SG11201811434RA SG11201811434RA SG11201811434RA SG 11201811434R A SG11201811434R A SG 11201811434RA SG 11201811434R A SG11201811434R A SG 11201811434RA SG 11201811434R A SG11201811434R A SG 11201811434RA SG 11201811434R A SG11201811434R A SG 11201811434RA
Authority
SG
Singapore
Prior art keywords
california
international
san diego
road
jolla
Prior art date
Application number
SG11201811434RA
Inventor
Wil Joseph Andahazy
Arnab K Chatterjee
Case W Mcnamara
Federico C Beasley
Anders Mikal Eliasen
Hank Michael James Petrassi
Jason T Roland
Timothy Wells
Olga Vladimirovna Zatolochnaya
Fei Zhou
Peter G Schultz
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of SG11201811434RA publication Critical patent/SG11201811434RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/65—Halogen-containing esters of unsaturated acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/32—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1 MEM 0 11101 HOE 010 1111 1 0 01 OH OH OH 1101 IRO 111101111011 Iii Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\"1 WO 2017/222996 Al 28 December 2017 (28.12.2017) WIP0 I PCT (51) International Patent Classification: Jason T.; 15698 Via Montecristo, San Diego, California A61K 31/122 (2006.01) A61P 33/02 (2006.01) 92127 (US). WELLS, Timothy; Chemin des Cornillons A61K 31/215 (2006.01) CO7C 50/32 (2006.01) 40A, 1292 Chambesy (CH). ZATOLOCHNAYA, Olga (21) International Application Number: Vladimirovna; 50 Saw Mill Road, Apt. 14323, Danbury, PCT/US2017/038173 Connecticut 06810 (US). ZHOU, Fei; 4435 Nobel Drive, Unit 48, San Diego, California 92122 (US). SCHULTZ, (22) International Filing Date: Peter G.; 1650 La Jolla Rancho Road, La Jolla, California 19 June 2017 (19.06.2017) 92037 (US). (25) Filing Language: English (74) Agent: HARDT, Ingo H.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (26) Publication Language: English (US). (30) Priority Data: (81) Designated States (unless otherwise indicated, for every 62/352,455 20 June 2016 (20.06.2016) US kind of national protection available): AE, AG, AL, AM, (71) Applicant: THE CALIFORNIA INSTITUTE FOR AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, BIOMEDICAL RESEARCH [US/US]; 11119 North Tor- CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, rey Pines Road, Suite 100, La Jolla, California 92037 (US). DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, — (72) Inventors: ANDAHAZY, Wil Joseph; 5684 Clouds Mill KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, Drive, Alexandria, Virginia 22310 (US). CHATTERJEE, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, Arnab K.; 13268 Torrey Crest Court, San Diego, Cali- OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, fornia 92129 (US). MCNAMARA, Case W.; 469 Chest- SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, nut Avenue, San Marcos, California 92069 (US). BEAS- TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = LEY, Federico C.; 7275 Calabria Court, #69, San Diego, California 92122 (US). ELIASEN, Anders Mikal; 7954 (84) Designated States (unless otherwise indicated, for every = _ Avenida Navidad, Apt. 97, San Diego, California 92122 kind of regional protection available): ARIPO (BW, GH, (US). PETRASSI, Hank Michael James; 4695 Serena- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, to Place, San Diego, California 92130 (US). ROLAND, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = = (54) Title: ANTIMALARIAL COMPOSITIONS AND USES THEREOF = = FIG. 38 = = = 100000 2 c = = 10000 = = 1000 c ; rough :=. 1000 nM = = t 100 — = 10 U 11 10 0 15 ,tD Time (weeks) 01 01 ei ei ei Top curve (squares): Compound 33 (60 mg/kg) IN Bottom curve (circles): Compound 33 (20 mg/kg) 11 © (57) ei : Provided herein are compounds, compositions and method of using thereof to treat or prevent malaria. C [Continued on next page] WO 2017/222996 Al IMEDIMOM0101011MMEMODIOHOHOHEIERODEVOIMIE EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))
SG11201811434RA 2016-06-20 2017-06-19 Antimalarial compositions and uses thereof SG11201811434RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662352455P 2016-06-20 2016-06-20
PCT/US2017/038173 WO2017222996A1 (en) 2016-06-20 2017-06-19 Antimalarial compositions and uses thereof

Publications (1)

Publication Number Publication Date
SG11201811434RA true SG11201811434RA (en) 2019-01-30

Family

ID=60784061

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201811434RA SG11201811434RA (en) 2016-06-20 2017-06-19 Antimalarial compositions and uses thereof
SG10202112759SA SG10202112759SA (en) 2016-06-20 2017-06-19 Antimalarial compositions and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202112759SA SG10202112759SA (en) 2016-06-20 2017-06-19 Antimalarial compositions and uses thereof

Country Status (12)

Country Link
US (3) US10947176B2 (en)
EP (1) EP3471711A4 (en)
JP (1) JP2019523779A (en)
KR (1) KR20190020774A (en)
CN (2) CN114569552A (en)
AU (1) AU2017281426B2 (en)
BR (1) BR112018076619A2 (en)
CA (1) CA3028392A1 (en)
EA (1) EA201990064A1 (en)
MA (1) MA45411A (en)
SG (2) SG11201811434RA (en)
WO (1) WO2017222996A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3028392A1 (en) * 2016-06-20 2017-12-28 The Scripps Research Institute Antimalarial compositions and uses thereof
US20210330585A1 (en) * 2018-09-04 2021-10-28 President And Fellows Of Harvard College Method for reducing parasite burden in a mosquito
WO2021231335A1 (en) * 2020-05-11 2021-11-18 Oregon Health & Science University Novel intermediates and synthesis for endochin-like quinolone compounds
WO2022144920A1 (en) * 2020-12-30 2022-07-07 Ipca Laboratories Limited Atovaquone prodrugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206268A (en) * 1988-08-16 1993-04-27 Burroughs Wellcome Co. Medicaments
GB8819477D0 (en) * 1988-08-16 1988-09-21 Wellcome Found Medicaments
DE68914930T2 (en) 1988-08-16 1994-08-18 Wellcome Found Naphtoquinones for the treatment and prophylaxis of Pneumocystis carinii infections.
US5021426A (en) * 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives
GB9207517D0 (en) 1992-04-06 1992-05-20 Wellcome Found Heterocyclic compounds
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
ITMI20070941A1 (en) * 2007-05-09 2008-11-10 Chimico Internazi0Nale S P A L PROCEDURE FOR THE PREPARATION OF TRANS2.3-DISPOSITED NAFTOCHINONES
CA3028392A1 (en) * 2016-06-20 2017-12-28 The Scripps Research Institute Antimalarial compositions and uses thereof

Also Published As

Publication number Publication date
US20190202766A1 (en) 2019-07-04
CA3028392A1 (en) 2017-12-28
EA201990064A1 (en) 2019-05-31
US20210179524A1 (en) 2021-06-17
KR20190020774A (en) 2019-03-04
SG10202112759SA (en) 2021-12-30
US20230111793A1 (en) 2023-04-13
AU2017281426B2 (en) 2021-10-14
CN109715147A (en) 2019-05-03
MA45411A (en) 2019-04-24
EP3471711A1 (en) 2019-04-24
EP3471711A4 (en) 2020-02-19
US11485697B2 (en) 2022-11-01
WO2017222996A1 (en) 2017-12-28
BR112018076619A2 (en) 2019-04-02
CN114569552A (en) 2022-06-03
JP2019523779A (en) 2019-08-29
AU2017281426A1 (en) 2019-01-17
US10947176B2 (en) 2021-03-16

Similar Documents

Publication Publication Date Title
SG11201811434RA (en) Antimalarial compositions and uses thereof
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201910198UA (en) Multibiotic agents and methods of using the same
SG11201808990QA (en) Compositions for topical application of compounds
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201811549UA (en) Boronic acid derivatives and therapeutic uses thereof
SG11201906885TA (en) Methods for the administration of certain vmat2 inhibitors
SG11201805186VA (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
SG11201909927RA (en) Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201901273TA (en) Blood plasma fractions as a treatment for aging-associated cognitive disorders
SG11201809751XA (en) Egfr inhibitor compounds
SG11201806583XA (en) Compositions containing tucaresol or its analogs
SG11201908181XA (en) Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201805385QA (en) Bromodomain and extra-terminal protein inhibitor combination therapy
SG11201811351WA (en) Compositions and methods for forming stable, liquid metal oxide/hydroxide formulations
SG11201909735YA (en) Therapeutic compounds and compositions, and methods of use thereof
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201809882XA (en) Pharmaceutical combinations for treating cancer